The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | CAR T-cell therapy for R/R secondary CNS lymphoma: real-world outcomes
Sairah Ahmed, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of CAR T-cell therapy products, such as axicabtagene ciloleucel (axi-cel), for treating relapsed/refractory (R/R) secondary central nervous system (CNS) lymphoma. Dr Ahmed notes that this difficult-to-treat patient population was excluded from the pivotal trials for axi-cel. However, real-world data suggest that CAR-T can be curative for a proportion of patients and that the safety profile is comparable to that seen in other patient populations.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So patients with secondary CNS lymphoma were not included in the pivotal trials for axi-cel and this is a patient population that we are seeing more and more of in our clinics and a fairly difficult patient population to treat; either because they don’t have a treatment response and therefore are not eligible for a curative intent treatment such as autologous stem cell transplant consolidation after high-dose chemotherapy or they’re older patients and maybe are not transplant eligible...
So patients with secondary CNS lymphoma were not included in the pivotal trials for axi-cel and this is a patient population that we are seeing more and more of in our clinics and a fairly difficult patient population to treat; either because they don’t have a treatment response and therefore are not eligible for a curative intent treatment such as autologous stem cell transplant consolidation after high-dose chemotherapy or they’re older patients and maybe are not transplant eligible. So CAR T-cell therapy is potentially a curative intent treatment for those patients. Data suggests that there is a population of patients who will be cured of their CNS lymphoma with CAR T-cell therapy and the safety parameters seem to be very similar to what we’ve seen in other patient populations including CRS and ICANS. So there’s no new safety signal or worse safety signal in these patients, which demonstrates that it’s still a very safe treatment even if they have active CNS lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
